K2 PRINCIPAL FUND, L.P.

Position in ABVX — Abivax S.A.

CIK 1461790 TORONTO, A6

Back to ABVX Full portfolio

Position in ABVX

as of Mar 31, 2026 · filed May 14, 2026 Compact

Position Value

$5,984,060

+$2,949,823 QoQ

Shares Held

53,741

+138.8% QoQ

Ownership

0.062%

of shares outstanding

% of Portfolio

2.09%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Dec 2025

2 quarters on record

Voting authority Sole 100% Shared 0% None 0%

Common Shares in ABVX Over Time

Shares Held

Position Value (USD)

Derivatives in ABVX

reported options exposure · as of Mar 31, 2026

CallValue

$1,113,500

CallShares

10,000

PutValue

PutShares

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Mar 31, 2026

K2 PRINCIPAL FUND, L.P. holds $12,417,536 across 3 Biotechnology names. ABVX ranks #1 (48.2% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	ABVX	Abivax S.A. This page	53,741	$5,984,060
2	SPRY	ARS Pharmaceuticals, Inc.	559,697	$4,494,366
3	QURE	uniQure N.V.	118,600	$1,939,110

All Filings in ABVX

Export CSV

4 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$1,113,500	10,000	-81.4%	Call	Sole	2026-05-14
2026-03-31	$5,984,060	53,741	+138.8%	Shares	Sole	2026-05-14
2025-12-31	$3,034,237	22,500	+125.0%	Shares	Sole	2026-02-13
2025-12-31	$1,348,550	10,000	—	Call	Sole	2026-02-13
No filing history on record for this holder in this stock.